Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 2/3 1

Status

Completed 174Terminated 53Recruiting 27Withdrawn 15Active not recruiting 15Unknown 7Not yet recruiting 4Suspended 1No longer available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 7Other hematologic neoplasm 4

Conditions

Leukemia, Myeloid, Acute 139Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Leukemia 37Leukemia, Lymphocytic, Chronic, B-Cell 35Recurrence 24Myelodysplastic Syndromes 23Lymphoma 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Neoplasms 12Multiple Myeloma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasm, Residual 8Motor Activity 8Lymphoma, Non-Hodgkin 8Lymphoma, Follicular 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell 7Leukemia, B-Cell 7Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Plasma Cell 5Leukemia, Myeloid, Chronic-Phase 5Febrile Neutropenia 5Burkitt Lymphoma 5Waldenstrom Macroglobulinemia 4Primary Myelofibrosis 4Pain 4Neoplasm Metastasis 4

Interventions

luspatercept 1Tacrolimus 1Resistance Training 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Primary Myelofibrosis × Other hematologic neoplasm × Clear all
NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

NCT07302776 2026-04-17

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Stanford University

Phase 1 Not yet recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07527221 2026-04-14

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Eilean Therapeutics

Phase 1 Not yet recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT07518940 2026-04-09

ENERGIA

University of Turin, Italy

Phase NA Not yet recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Motor Activity, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡